Beyfortus, the new monoclonal antibody injection, similarly reduces the risk of RSV in infants for about five months—or one ...

The respiratory virus is the leading cause of hospitalisation for infants, with 12,000 babies admitted each year. Before next ...

A new government program will give pregnant mothers and newborns free access to RSV vaccines, a move that is expected to ...

This season will be the first time in Ontario that nirsevimab (sold under the brand name Beyfortus) is used to protect babies ...

Sanofi announced that Beyfortus (nirsevimab) will be broadly available for babies born in Ontario, Quebec, Nunavut, Northwest ...

Nationwide RSV immunisation program to keep 10,000 babies out of hospitalImmunisation advocates are heralding the Albanese Government's commitment to ...

RSV vaccination for infants and mothers should be administered either in the hospital or directly from a primary health-care ...

BEYFORTUS® Product Monograph, Sanofi Pasteur Limited, June 14, 2024. ii BEYFORTUS® Product Monograph, Sanofi Pasteur Limited, June 14, 2024. iii ...

Sanofi (SNY) announced Beyfortus will be broadly available for babies born in Ontario, Quebec, Nunavut, Northwest Territories, and the Yukon ...

Beyfortus is the first long-acting antibody approved in Canada for the prevention of RSV lower respiratory tract disease in newborns and infants through their first RSV season. Sanofi noted that ...

Beyfortus ® is the first immunization designed for all infants to help prevent RSV lower respiratory tract disease through their first RSV season. Beyfortus ® is also indicated for children up ...